Should I buy or sell Orthofix Medical stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orthofix Medical in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" OFIX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OFIX, but not buy additional shares or sell existing shares. View OFIX analyst ratings or view top-rated stocks .

What is Orthofix Medical's stock price target for 2024?

3 Wall Street analysts have issued 1-year price objectives for Orthofix Medical's stock. Their OFIX share price targets range from $15.00 to $16.00. On average, they anticipate the company's share price to reach $15.50 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price. View analysts price targets for OFIX or view top-rated stocks among Wall Street analysts .

How have OFIX shares performed in 2024?

Orthofix Medical's stock was trading at $13.48 on January 1st, 2024. Since then, OFIX shares have decreased by 2.8% and is now trading at $13.10. View the best growth stocks for 2024 here .

When is Orthofix Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our OFIX earnings forecast .

How were Orthofix Medical's earnings last quarter?

Orthofix Medical Inc. (NASDAQ:OFIX) released its quarterly earnings data on Tuesday, March, 5th. The medical device company reported ($0.59) EPS for the quarter, beating analysts' consensus estimates of ($0.60) by $0.01. The medical device company had revenue of $200.42 million for the quarter. Orthofix Medical had a negative net margin of 20.28% and a negative trailing twelve-month return on equity of 10.63%.

What ETFs hold Orthofix Medical's stock?

ETFs with the largest weight of Orthofix Medical (NASDAQ:OFIX) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE) . Invesco Nasdaq Future Gen 200 ETF (QQQS) .

What guidance has Orthofix Medical issued on next quarter's earnings?

Orthofix Medical issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $785.0 million-$795.0 million, compared to the consensus revenue estimate of $798.6 million.

What is Brad Mason's approval rating as Orthofix Medical's CEO?

32 employees have rated Orthofix Medical Chief Executive Officer Brad Mason on Glassdoor.com . Brad Mason has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Orthofix Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthofix Medical investors own include AbbVie (ABBV) , Enterprise Products Partners (EPD) , Edwards Lifesciences (EW) , Gilead Sciences (GILD) , Biogen (BIIB) , Pfizer (PFE) , Exxon Mobil (XOM) , Advanced Micro Devices (AMD) , bluebird bio (BLUE) and Esperion Therapeutics (ESPR) .

How do I buy shares of Orthofix Medical?

Shares of OFIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OFIX

Orthofix Medical (OFIX) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free OFIX Stock Alerts

$13.10

+0.08 (+0.61%)

(As of 04/19/2024 ET)

Compare

Today's Range: $12.97
▼
$13.25
50-Day Range: $13.00
▼
$14.64
52-Week Range: $9.57
▼
$21.60

Volume: 285,114 shs
Average Volume: 409,207 shs
Market Capitalization: $490.07 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.50

Get Orthofix Medical alerts:

Orthofix Medical MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 18.3% Upside
$15.50 Price Target
Short Interest: Bearish
10.26% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.51) to ($0.69) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.59 out of 5 stars

Medical Sector

858th out of 911 stocks

Surgical & Medical Instruments Industry

90th out of 97 stocks

2.0

Analyst's Opinion

Consensus Rating
Orthofix Medical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Orthofix Medical has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
10.26% of the outstanding shares of Orthofix Medical have been sold short.
Short Interest Ratio / Days to Cover
Orthofix Medical has a short interest ratio ("days to cover") of 9.3.
Change versus previous month
Short interest in Orthofix Medical has recently increased by 3.50%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Orthofix Medical does not currently pay a dividend.
Dividend Growth
Orthofix Medical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OFIX.

1.7

News and Social Media Coverage

News Sentiment
Orthofix Medical has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Orthofix Medical this week, compared to 3 articles on an average week.
Search Interest
5 people have searched for OFIX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Orthofix Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Orthofix Medical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.70% of the stock of Orthofix Medical is held by insiders.
Percentage Held by Institutions
89.76% of the stock of Orthofix Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Orthofix Medical are expected to grow in the coming year, from ($1.51) to ($0.69) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Orthofix Medical is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Orthofix Medical is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Orthofix Medical has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Orthofix Medical Stock (NASDAQ:OFIX)

Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.

OFIX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OFIX Stock News Headlines

April 16, 2024 | finance.yahoo.com

Orthofix Names Andres Cedron as New Chief Legal Officer

April 11, 2024 | americanbankingnews.com

Comparing InspireMD (NYSE:NSPR) & Orthofix Medical (NASDAQ:OFIX)

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 9, 2024 | americanbankingnews.com

Orthofix Medical (NASDAQ:OFIX) Shares Pass Above 200 Day Moving Average of $12.85

April 1, 2024 | uk.finance.yahoo.com

Mesenchymal Stem Cells (MSCs) Advancements & Global Market Potential Highlighted in Comprehensive Strategic Report

March 28, 2024 | tmcnet.com

BRIJ Medical Bolsters Leadership Team: John Grotting Named Chairman, Bob Zollars and Jim Hinrichs Join Board

March 7, 2024 | finance.yahoo.com

Orthofix Medical Inc (OFIX) Reports Significant Sales Growth and Improved EBITDA in Q4 and Full ...

March 6, 2024 | ca.finance.yahoo.com

Orthofix Medical Inc. (OM2.F)

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 6, 2024 | msn.com

Orthofix GAAP EPS of -$0.59 misses by $0.10, revenue of $200.4M beats by $4.83M

March 6, 2024 | finance.yahoo.com

Q4 2023 Orthofix Medical Inc Earnings Call

March 5, 2024 | investorplace.com

OFIX Stock Earnings: Orthofix Medical Misses EPS, Beats Revenue for Q4 2023

March 5, 2024 | seekingalpha.com

Orthofix Medical Inc. 2023 Q4 - Results - Earnings Call Presentation

March 5, 2024 | businesswire.com

Orthofix Reports Fourth Quarter and Full Year 2023 Results

March 5, 2024 | businesswire.com

Orthofix Reports Fourth Quarter and Full Year 2023 Results

March 4, 2024 | markets.businessinsider.com

Here's what Wall Street expects from Orthofix Medical's earnings report

February 29, 2024 | finance.yahoo.com

Orthofix Announces New President for Bone Growth Therapies Business

February 21, 2024 | finance.yahoo.com

Orthofix Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for March 5, 2024

February 21, 2024 | businesswire.com

Orthofix Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for March 5, 2024

January 18, 2024 | finance.yahoo.com

Orthofix Announces Commercial Partnership with MRIguidance

January 16, 2024 | finance.yahoo.com

Julie Andrews Begins as New Chief Financial Officer at Orthofix

January 9, 2024 | markets.businessinsider.com

Orthofix Medical Preliminary Q4 Net Sales Up 63.8% - Quick Facts

January 9, 2024 | finance.yahoo.com

Orthofix Medical Inc. Announces Preliminary 2023 Fourth Quarter and Full-Year Net Sales Results

January 8, 2024 | msn.com

Orthofix Medical appoints CEO, CFO

December 27, 2023 | finance.yahoo.com

Orthofix (OFIX) Releases New Data for Spinal Fusion Procedures

December 21, 2023 | finance.yahoo.com

Orthofix Announces Publication of New Data Supporting Use of PEMF Stimulation in Lumbar Spine Fusion Procedures for Patients at Risk of Pseudarthrosis

December 12, 2023 | msn.com

Orthofix appoints three new independent directors

See More Headlines

Receive OFIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orthofix Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Current Symbol: NASDAQ:OFIX
CUSIP: N6748L10
CIK: 884624
Web: www.orthofix.com
Phone: (214) 937-2000
Fax: 599 9 461 6978
Employees: 1,634
Year Founded: 1980

Price Target and Rating

Average Stock Price Target: $15.50
High Stock Price Target: $16.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +18.3%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-151,400,000.00
Net Margins: -20.28%
Pretax Margin: -19.91%
Return on Equity: -10.63%
Return on Assets: -7.34%

Debt

Debt-to-Equity Ratio: 0.19
Current Ratio: 2.54
Quick Ratio: 1.20

Sales & Book Value

Annual Sales: $746.64 million
Price / Sales: 0.66
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $16.11 per share
Price / Book: 0.81

Miscellaneous

Outstanding Shares: 37,410,000
Free Float: 35,649,000
Market Cap: $490.07 million
Optionable: Optionable
Beta: 1.04

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Ms. Kimberley A. Elting (Age 59)
President of Global Orthopedics
Comp: $766.67k
Mr. Kevin J. Kenny (Age 59)
President of Global Spine Business
Comp: $607.64k
Mr. Massimo Calafiore
President, CEO & Director
Ms. Julie B. Andrews (Age 53)
Chief Financial Officer
Mr. Roberto Donadello
Senior Vice President of Global Operations
Dr. Frank Vizesi Ph.D.
Chief Scientific Officer
Mr. Dan E. Yarbrough
Vice President of Investor Relations
Ms. Jill Mason
Interim Chief Ethics & Compliance Officer and VP of Corporate Counsel
Mr. Lucas S. Vitale (Age 47)
Chief People & Business Operations Officer
Mr. Ehab M. Esmail (Age 52)
Senior Vice President of Global Quality, Regulatory & Clinical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OFIX Stock Analysis - Frequently Asked Questions

Should I buy or sell Orthofix Medical stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orthofix Medical in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" OFIX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OFIX, but not buy additional shares or sell existing shares.
View OFIX analyst ratings or view top-rated stocks.
What is Orthofix Medical's stock price target for 2024?: 3 Wall Street analysts have issued 1-year price objectives for Orthofix Medical's stock. Their OFIX share price targets range from $15.00 to $16.00. On average, they anticipate the company's share price to reach $15.50 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price.
View analysts price targets for OFIX or view top-rated stocks among Wall Street analysts.
How have OFIX shares performed in 2024?: Orthofix Medical's stock was trading at $13.48 on January 1st, 2024. Since then, OFIX shares have decreased by 2.8% and is now trading at $13.10.
View the best growth stocks for 2024 here.
When is Orthofix Medical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our OFIX earnings forecast.
How were Orthofix Medical's earnings last quarter?: Orthofix Medical Inc. (NASDAQ:OFIX) released its quarterly earnings data on Tuesday, March, 5th. The medical device company reported ($0.59) EPS for the quarter, beating analysts' consensus estimates of ($0.60) by $0.01. The medical device company had revenue of $200.42 million for the quarter. Orthofix Medical had a negative net margin of 20.28% and a negative trailing twelve-month return on equity of 10.63%.
What ETFs hold Orthofix Medical's stock?: ETFs with the largest weight of Orthofix Medical (NASDAQ:OFIX) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What guidance has Orthofix Medical issued on next quarter's earnings?: Orthofix Medical issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $785.0 million-$795.0 million, compared to the consensus revenue estimate of $798.6 million.
What is Brad Mason's approval rating as Orthofix Medical's CEO?: 32 employees have rated Orthofix Medical Chief Executive Officer Brad Mason on Glassdoor.com. Brad Mason has an approval rating of 73% among the company's employees.
What other stocks do shareholders of Orthofix Medical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Orthofix Medical investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Edwards Lifesciences (EW), Gilead Sciences (GILD), Biogen (BIIB), Pfizer (PFE), Exxon Mobil (XOM), Advanced Micro Devices (AMD), bluebird bio (BLUE) and Esperion Therapeutics (ESPR).
How do I buy shares of Orthofix Medical?: Shares of OFIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OFIX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial